Multivalent CLTX-CAR γδ T-Cells for Persistent GBM Cytotoxicity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing CAR T-cell therapies have shown limited efficacy against glioblastoma (GBM) and other cancers, with a need for improved treatments that enhance cytotoxicity and persistence of γδ T-cells.

Innovation Solution

Engineering γδ T-cells with a multivalent chlorotoxin (CLTX)-based chimeric antigen receptor (CAR) comprising two CLTX peptides in the extracellular antigen-binding domain, optionally with a survival factor conferring resistance to chemotherapeutic agents, without an intracellular signaling domain.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If a single CLTX peptide is used in the extracellular antigen-binding domain of CAR, then the CAR structure is simpler and easier to manufacture, but the cytotoxicity and persistence against GBM cells is insufficient

Engineering Contradiction:

ImproveCAR structure simplicityVSAvoidcytotoxicity and persistence

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent combines multiple CLTX peptides (two or more) into a single multivalent CAR extracellular antigen-binding domain. This merging approach increases the density of antigen-binding sites on the CAR, thereby enhancing cytotoxicity and persistence against GBM cells while maintaining a relatively simple overall CAR structure that remains feasible to manufacture.

Inventive Principle:

Principle #5Merging (Combining)

2Reliability

If more than two CLTX peptides are added to the extracellular antigen-binding domain, then antigen binding capacity increases, but the CAR is not properly presented on the cell surface and activation does not enhance

Engineering Contradiction:

Improveantigen binding capacityVSAvoidCAR cell surface presentation

Core Design Contradiction:

ReliabilityVSManufacturing precision

Solution Approach 1:

The patent optimizes the number of CLTX peptides in the extracellular antigen-binding domain to exactly two or more, but not exceeding a certain threshold. This parameter optimization ensures proper CAR folding, stability, and cell surface presentation while maintaining enhanced antigen binding capacity. The specific stoichiometry of two peptides appears to be the optimal balance point identified through experimentation.

Inventive Principle:

Principle #35Parameter changes

3Productivity

If GBM treatment with conventional CAR T-cell therapies is used, then treatment is administered, but the median survival remains less than 15 months with limited efficacy

Engineering Contradiction:

Improvetreatment administrationVSAvoidsurvival outcome

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent creates a composite CAR structure that integrates multiple CLTX peptide sequences into a single functional antigen-binding domain. This composite design leverages the specific properties of CLTX (affinity for MMP2 and CLCN3 on GBM cells) while achieving enhanced therapeutic outcomes through multivalency, resulting in improved survival outcomes compared to conventional single-peptide CAR therapies.

Inventive Principle:

Principle #40Composite materials

Data Source

PatentUS20260078529A1Multivalent Chlorotoxin Chimeric Antigen Receptors

Publication Date: 2026.03.19 IN8BIO INC

AI summary

Described are γδ T-cells that express a multivalent CLTX-CAR and also express a survival factor, a population of the γδ T-cells that express a multivalent CLTX-CAR and the survival factor, pharmaceutical compositions thereof, and methods of treating cancer or a tumor in a subject comprising administering to a subject an effective amount of the multivalent CLTX-CAR γδ T-cells and co-administering a chemotherapeutic agent, e.g., the chemotherapeutic agent to which the survival factor confers resistance.